Why the study?
Does troglitazone improve left ventricular diastolic dynamics in a spontaneous diabetic rat model?
Does troglitazone improve left ventricular diastolic dynamics in a spontaneous diabetic rat model?
Troglitazone improves left ventricular diastolic dynamics in a diabetic rat model at the prediabetic stage.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for troglitazone in diabetic diastolic dysfunction; leaves open translation to human HFpEF.
Troglitazone, an oral antidiabetic agent, has hypoglycemic effects in insulin-resistant animal models and humans. This study was conducted to evaluate its effect on left ventricular diastolic dynamics of a spontaneous diabetic (DM) rat model. Twenty DM rats and 20 age-matched nonDM rats were used, and 10 of each group were treated with troglitazone as a 0.2% food admixture for 10 weeks. At 5 and 15 weeks of age, Doppler echocardiography and M-mode echocardiography were performed. Troglitazone treatment significantly improved the left ventricular diastolic dynamics of DM rats: deceleration time (msec) of early diastolic inflow decreased significantly (treated 52 +/- 3 vs untreated 64 +/- 5, p = 0.0002), and peak velocity of early transmitral inflow (cm/sec) increased significantly (treated 96 +/- 7 vs untreated 86 +/- 8, p = 0.0216). The data suggest that troglitazone improves left ventricular diastolic dynamics of a DM rat model at prediabetic stage.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: